首页 > 最新文献

European Journal of Cancer (1965)最新文献

英文 中文
The In Vitro mammary gland response to mammotropic hormones in mice with different mammary tumorigenesis 不同乳腺肿瘤发生小鼠体外乳腺对促乳激素的反应
Pub Date : 1981-05-01 DOI: 10.1016/0014-2964(81)90051-7
Hiroshi Nagasawa, Reiko Yanai

Mammary gland DNA synthesis estimated by the in vitro incorporation of [3H]thymidine in response to mammotropic hormones was compared between high and low mammary tumor strains of virgin mice (SHN and SLN). In SHN, mammary gland DNA synthesis when cultured in the medium containing insulin (I), aldosterone (A), estradiol-17β (E), progesterone, prolactin (PRL) and growth hormone (GH) showed a peak on day 2 of culture and declined thereafter. Quite the opposite was the case in SLN mammary glands. There was little strain-difference in mammary gland DNA synthesis when cultured for 6 days in the medium containing complete hormone mixture. However, DNA synthesis of SHN mammary glands cultured in the medium deficient in PRL was less than one-third of the control, whereas that of SLN glands was two-thirds of the control. Moreover, mammary gland DNA synthesis was decreased significantly by deficiency in GH or E in SHN strain only. In both strains, mammary gland DNA synthesis declined with an increasing dose of PRL when cultured in the medium containing I, A and PRL, which was associated with an activated secretory function. However, the changes were much more marked in SHN than in SLN. The results have demonstrated the higher dependency of SHN mammary glands than SLN glands upon mammotropic hormones, especially PRL. They further indicate that mammary gland potential for both growth and function is well reflected by mammary gland sensitivity to PRL.

通过体外掺入[3H]胸腺嘧啶对促乳激素的响应来估计乳腺DNA的合成,比较了初生小鼠高、低乳腺肿瘤品系(SHN和SLN)的乳腺DNA合成。在SHN中,在含有胰岛素(I)、醛固酮(A)、雌二醇-17β (E)、孕酮、催乳素(PRL)和生长激素(GH)的培养基中培养时,乳腺DNA合成在培养第2天达到峰值,随后下降。SLN乳腺的情况正好相反。在含有完全激素混合物的培养基中培养6天后,乳腺DNA合成的品系差异不大。然而,在缺乏PRL的培养基中培养的SHN乳腺的DNA合成低于对照的三分之一,而SLN乳腺的DNA合成为对照的三分之二。此外,仅在SHN菌株中,GH或E的缺乏显著降低了乳腺DNA的合成。在含有I、A和PRL的培养基中培养时,两株菌株的乳腺DNA合成均随着PRL剂量的增加而下降,这与分泌功能的激活有关。然而,SHN的变化要比SLN明显得多。结果表明,SHN型乳腺对促乳激素的依赖性高于SLN型乳腺,尤其是PRL。他们进一步表明,乳腺对PRL的敏感性很好地反映了乳腺生长和功能的潜力。
{"title":"The In Vitro mammary gland response to mammotropic hormones in mice with different mammary tumorigenesis","authors":"Hiroshi Nagasawa,&nbsp;Reiko Yanai","doi":"10.1016/0014-2964(81)90051-7","DOIUrl":"10.1016/0014-2964(81)90051-7","url":null,"abstract":"<div><p>Mammary gland DNA synthesis estimated by the <em>in vitro</em> incorporation of [<sup>3</sup>H]thymidine in response to mammotropic hormones was compared between high and low mammary tumor strains of virgin mice (SHN and SLN). In SHN, mammary gland DNA synthesis when cultured in the medium containing insulin (I), aldosterone (A), estradiol-<em>17</em>β (E), progesterone, prolactin (PRL) and growth hormone (GH) showed a peak on <em>day 2</em> of culture and declined thereafter. Quite the opposite was the case in SLN mammary glands. There was little strain-difference in mammary gland DNA synthesis when cultured for <em>6 days</em> in the medium containing complete hormone mixture. However, DNA synthesis of SHN mammary glands cultured in the medium deficient in PRL was less than one-third of the control, whereas that of SLN glands was two-thirds of the control. Moreover, mammary gland DNA synthesis was decreased significantly by deficiency in GH or E in SHN strain only. In both strains, mammary gland DNA synthesis declined with an increasing dose of PRL when cultured in the medium containing I, A and PRL, which was associated with an activated secretory function. However, the changes were much more marked in SHN than in SLN. The results have demonstrated the higher dependency of SHN mammary glands than SLN glands upon mammotropic hormones, especially PRL. They further indicate that mammary gland potential for both growth and function is well reflected by mammary gland sensitivity to PRL.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Pages 503-507"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90051-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18076974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
High dose chemotherapy and autologous bone marrow transplantation in acute leukemias, malignant lymphomas and solid tumors 大剂量化疗和自体骨髓移植治疗急性白血病、恶性淋巴瘤和实体瘤
Pub Date : 1981-05-01 DOI: 10.1016/0014-2964(81)90058-X
N.C. Gorin , R. David , J. Stachowiak , Ch. Salmon , J.C. Petit , Y. Parlier , A. Najman , G. Duhamel

Twenty-three adult patients with end stage and/or poor prognosis malignancies (6 solid tumors, 6 malignant lymphomas, 11 acute leukemias) were treated by high dose chemotherapy, with (16 patients) or without (7 patients) reinfusion of cryopreserved autologous marrow. Eighteen patients were treated by the TACC regimen (cyclophosphamide 45 mg/kg days 1–4, ARA-C 100 mg/m2 q 12 hr days 1–4, 6-thioguanine 100 mg/m2 q 12 hr days 1–4, CCNU 200 mg/m2 day 2) and others received high dose combination chemotherapy regimens designed specifically for their anticipated tumor sensitivity. Additional radiotherapy was delivered in three cases. The results were analysed for toxicity, kinetics of recovery of hematopoiesis, and anti-tumor effects. All patients receiving cryopreserved marrow engrafted successfully and none died, although severe sepsis occured in six cases. In contrast, of the seven patients who did not receive cryopreserved marrow following the TACC regimen, three died from aplasia on days 15, 24 and 33. Recovery of leukocytes (WBC) and platelets in peripheral blood occurred twice as fast in patients with cryopreserved marrow: patients with solid tumors and malignant lymphomas recovered a WBC count of 1000/mm3 and a platelet count of 50,000/mm3 on day 11, regardless of the nature of the high dose therapy. Patients with acute leukemia had slightly delayed kinetics with recovery of leukocytes (>1000/mm3) and platelets (>50,000/mm3) occurring on day 18. Five of the six patients with solid tumors had a partial response (PR) on high dose therapy. Two patients with Hodgkin's disease achieved a complete remission, but the duration of the response was short (6 and 14 weeks). All four patients with non-Hodgkin's lymphomas went into complete remission (CR) and have remained free of disease without maintenance therapy for prolonged periods. All four patients with acute leukemias who received cryopreserved marrow went into complete remission and the duration of this CR paralleled the duration of the initial CR at the beginning of which the marrow had been harvested. One patient (AML) is still in CR 32 months after high dose therapy + autologous bone marrow transplantation (ABMT). Of the seven acute leukemia patients who did not receive cryopreserved marrow, only one had a CR of very short duration (1 month), and persisting, massive leukemic infiltration was demonstrated in five. These results demonstrate that ABMT is feasible in man and that it shortens the duration of aplasia following high dose therapy by about 50%. They also suggest that high dose therapy + ABMT should be included in the management of patients with acute leukemias, non-Hodgkin's lymphomas and some selected so

23例晚期和/或预后不良的恶性肿瘤成年患者(6例实体瘤、6例恶性淋巴瘤、11例急性白血病)接受了高剂量化疗,其中(16例)或不(7例)回输冷冻保存的自体骨髓。18名患者接受TACC方案治疗(环磷酰胺45 mg/kg第1-4天,ARA-C 100 mg/m2 q12小时第1-4天、6-硫鸟嘌呤100 mg/m2 q 12小时第2-4天,CCNU 200 mg/m2第2天),其他患者接受专为其预期肿瘤敏感性设计的高剂量联合化疗方案。3例患者接受了额外的放射治疗。对结果进行了毒性、造血恢复动力学和抗肿瘤作用分析。所有接受冷冻保存骨髓移植的患者都成功植入,没有一例死亡,尽管有6例发生了严重的败血症。相反,在TACC方案后未接受冷冻保存骨髓的7名患者中,有3名在第15、24和33天死于发育不全。冷冻保存骨髓的患者外周血中白细胞(WBC)和血小板的恢复速度是冷冻保存骨髓患者的两倍:无论高剂量治疗的性质如何,实体瘤和恶性淋巴瘤患者在第11天恢复的WBC计数为1000/mm3,血小板计数为50000/mm3。急性白血病患者具有轻微延迟的动力学,在第18天出现白细胞(>1000/mm3)和血小板(>50000/mm3)的恢复。六名实体瘤患者中有五名对高剂量治疗有部分反应(PR)。两名霍奇金病患者病情完全缓解,但反应持续时间较短(6周和14周)。所有四名非霍奇金淋巴瘤患者都进入了完全缓解期(CR),并且在没有长期维持治疗的情况下仍然没有疾病。接受冷冻保存骨髓的所有四名急性白血病患者都进入了完全缓解期,这种CR的持续时间与骨髓采集开始时的初始CR的持续期平行。一名患者(AML)在高剂量治疗+自体骨髓移植(ABMT)32个月后仍处于CR状态。在7名未接受骨髓冷冻保存的急性白血病患者中,只有1名患者的CR持续时间很短(1个月),5名患者出现持续的大量白血病浸润。这些结果表明,ABMT在男性中是可行的,并且它将高剂量治疗后发育不全的持续时间缩短了约50%。他们还建议,在治疗急性白血病、非霍奇金淋巴瘤和一些选定的实体瘤患者时,应包括高剂量治疗+ABM。
{"title":"High dose chemotherapy and autologous bone marrow transplantation in acute leukemias, malignant lymphomas and solid tumors","authors":"N.C. Gorin ,&nbsp;R. David ,&nbsp;J. Stachowiak ,&nbsp;Ch. Salmon ,&nbsp;J.C. Petit ,&nbsp;Y. Parlier ,&nbsp;A. Najman ,&nbsp;G. Duhamel","doi":"10.1016/0014-2964(81)90058-X","DOIUrl":"https://doi.org/10.1016/0014-2964(81)90058-X","url":null,"abstract":"<div><p>Twenty-three adult patients with end stage and/or poor prognosis malignancies (<em>6</em> solid tumors, <em>6</em> malignant lymphomas, <em>11</em> acute leukemias) were treated by high dose chemotherapy, with (<em>16</em> patients) or without (<em>7</em> patients) reinfusion of cryopreserved autologous marrow. Eighteen patients were treated by the TACC regimen (cyclophosphamide <em>45 mg/kg days 1–4</em>, ARA-C <em>100 mg/m<sup>2</sup> q 12 hr days 1–4, 6</em>-thioguanine <em>100 mg/m<sup>2</sup> q 12 hr days 1–4</em>, CCNU <em>200 mg/m<sup>2</sup> day 2</em>) and others received high dose combination chemotherapy regimens designed specifically for their anticipated tumor sensitivity. Additional radiotherapy was delivered in three cases. The results were analysed for toxicity, kinetics of recovery of hematopoiesis, and anti-tumor effects. All patients receiving cryopreserved marrow engrafted successfully and none died, although severe sepsis occured in six cases. In contrast, of the seven patients who did not receive cryopreserved marrow following the TACC regimen, three died from aplasia on days <em>15, 24</em> and <em>33</em>. Recovery of leukocytes (WBC) and platelets in peripheral blood occurred twice as fast in patients with cryopreserved marrow: patients with solid tumors and malignant lymphomas recovered a WBC count of <em>1000/mm<sup>3</sup></em> and a platelet count of <em>50,000/mm<sup>3</sup></em> on day <em>11</em>, regardless of the nature of the high dose therapy. Patients with acute leukemia had slightly delayed kinetics with recovery of leukocytes (&gt;<em>1000/mm<sup>3</sup></em>) and platelets (&gt;<em>50,000/mm<sup>3</sup></em>) occurring on day <em>18</em>. Five of the six patients with solid tumors had a partial response (PR) on high dose therapy. Two patients with Hodgkin's disease achieved a complete remission, but the duration of the response was short (<em>6</em> and <em>14 weeks</em>). All four patients with non-Hodgkin's lymphomas went into complete remission (CR) and have remained free of disease without maintenance therapy for prolonged periods. All four patients with acute leukemias who received cryopreserved marrow went into complete remission and the duration of this CR paralleled the duration of the initial CR at the beginning of which the marrow had been harvested. One patient (AML) is still in CR <em>32 months</em> after high dose therapy + autologous bone marrow transplantation (ABMT). Of the seven acute leukemia patients who did not receive cryopreserved marrow, only one had a CR of very short duration (<em>1 month</em>), and persisting, massive leukemic infiltration was demonstrated in five. These results demonstrate that ABMT is feasible in man and that it shortens the duration of aplasia following high dose therapy by about <em>50%</em>. They also suggest that high dose therapy + ABMT should be included in the management of patients with acute leukemias, non-Hodgkin's lymphomas and some selected so","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Pages 557-568"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90058-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72048510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 90
Third university of Arizona cancer center conference on human tumor cloning 第三届亚利桑那大学癌症中心人类肿瘤克隆会议
Pub Date : 1981-05-01 DOI: 10.1016/0014-2964(81)90063-3
{"title":"Third university of Arizona cancer center conference on human tumor cloning","authors":"","doi":"10.1016/0014-2964(81)90063-3","DOIUrl":"https://doi.org/10.1016/0014-2964(81)90063-3","url":null,"abstract":"","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Page 591"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90063-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72048511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent journal contents 最近的日记账内容
Pub Date : 1981-05-01 DOI: 10.1016/0014-2964(81)90068-2
{"title":"Recent journal contents","authors":"","doi":"10.1016/0014-2964(81)90068-2","DOIUrl":"https://doi.org/10.1016/0014-2964(81)90068-2","url":null,"abstract":"","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Page 594"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90068-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72048516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparison of DNA and DNA-binding protein levels in malignant disease 恶性疾病中DNA和DNA结合蛋白水平的比较
Pub Date : 1981-05-01 DOI: 10.1016/0014-2964(81)90055-4
Shalom A. Leon , Bernard Shapiro , Patricia Servi , Robert G. Parsons

Measurements of serum concentrations of DNA and the DNA-binding protein C3DP by radioimmunoassay showed that the levels of both substances tend to increase in cancer patients during active malignant disease. In most cases, the levels returned to normal during chemotherapy-induced remission; however, the changes in concentration for DNA and C3DP did not occur simultaneously, and no correlation was found between their levels. The sera of cancer patients contained a strong inhibitor of DNAse. We examined the possibility that C3DP may have such an inhibitory effect by binding to DNA and preventing the action of DNAse. The enzyme was fully active in the presence of purified C3DP, indicating that the DNAse inhibitor in cancer serum was a substance other than C3DP. Although the relationship between DNA and the DNA-binding protein remains unknown, their measurement may have diagnostic and prognostic value.

放射免疫测定法测定血清中DNA和DNA结合蛋白C3DP的浓度表明,在恶性肿瘤活动性期间,这两种物质的水平趋于升高。在大多数情况下,在化疗引起的缓解期间,水平恢复正常;然而,DNA和C3DP浓度的变化并不是同时发生的,它们的水平之间没有发现相关性。癌症患者的血清中含有较强的DNAse抑制剂。我们研究了C3DP可能通过与DNA结合并阻止DNAse的作用而具有这种抑制作用的可能性。该酶在纯化的C3DP存在下具有充分的活性,表明肿瘤血清中的DNAse抑制剂不是C3DP。虽然DNA和DNA结合蛋白之间的关系尚不清楚,但它们的测量可能具有诊断和预后价值。
{"title":"A comparison of DNA and DNA-binding protein levels in malignant disease","authors":"Shalom A. Leon ,&nbsp;Bernard Shapiro ,&nbsp;Patricia Servi ,&nbsp;Robert G. Parsons","doi":"10.1016/0014-2964(81)90055-4","DOIUrl":"10.1016/0014-2964(81)90055-4","url":null,"abstract":"<div><p>Measurements of serum concentrations of DNA and the DNA-binding protein C<em>3</em>DP by radioimmunoassay showed that the levels of both substances tend to increase in cancer patients during active malignant disease. In most cases, the levels returned to normal during chemotherapy-induced remission; however, the changes in concentration for DNA and C<em>3</em>DP did not occur simultaneously, and no correlation was found between their levels. The sera of cancer patients contained a strong inhibitor of DNAse. We examined the possibility that C<em>3</em>DP may have such an inhibitory effect by binding to DNA and preventing the action of DNAse. The enzyme was fully active in the presence of purified C<em>3</em>DP, indicating that the DNAse inhibitor in cancer serum was a substance other than C<em>3</em>DP. Although the relationship between DNA and the DNA-binding protein remains unknown, their measurement may have diagnostic and prognostic value.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Pages 533-538"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90055-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17945278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
First international symposium on the modulation and mediation of cancer by vitamins 第一届维生素对癌症的调节和调节国际研讨会
Pub Date : 1981-05-01 DOI: 10.1016/0014-2964(81)90064-5
{"title":"First international symposium on the modulation and mediation of cancer by vitamins","authors":"","doi":"10.1016/0014-2964(81)90064-5","DOIUrl":"https://doi.org/10.1016/0014-2964(81)90064-5","url":null,"abstract":"","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 5","pages":"Page 591"},"PeriodicalIF":0.0,"publicationDate":"1981-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90064-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72048512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Depopulation and repopulation of the R1H rhabdomyosarcoma of the rat after X-irradiation x射线照射后大鼠R1H横纹肌肉瘤的退群与复群
Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90245-0
H. Jung, H.-P. Beck, I. Brammer, F. Zywietz

Experiments were carried out to study the kinetics of depopulation and repopulation of the solid transplantable rhabdomyosarcoma R1H of the rat following local irradiation with a single X-ray dose of 15 Gy. Several parameters were sequentially measured over a time interval of 25 days after irradiation: The ratio of tumour to host cells was determined by flow cytometry; the numerical density of tumour cells was obtained by stereological analysis of histological slides; the clonogenic fraction of tumour cells was assayed by plating an appropriate number of tumour cells and scoring the colonies; tumour volume was assessed by measuring two tumour diameters at right angles to each other. All parameters investigated, except tumour volume, undergo drastic changes during the first 2 weeks after irradiation. From the directly measured parameters the following values and their variation with time could be derived. The number of host cells per tumour increased by a factor of 10 within the first 10 days after irradiation, probably due to infiltration by blood-borne host cells. During the same time interval, the number of tumour cells decreased by a factor of 5, whereas the total number of cells per tumour showed an increase by a factor of 4. Since the host cells are considerably smaller than the tumour cells, the cellular numerical density increased by a factor of 3, but approached the control level by Day 18 after irradiation. From the number of clonogenic and non-clonogenic tumour cells the kinetics of repopulation and depopulation was obtained. Repopulation of irradiated tumours by surviving tumour cells as well as removal of inactivated tumour cells began immediately after irradiation and proceeded with exponential kinetics. Repopulation occurred with a doubling time of 4.4 ± 0.3 days whereas inactivated tumour cells disintegrated with a halving time of 3.5 ± 0.7 days. There were no indications that proliferation of doomed cells contributed significantly to tumour growth after X-irradiation.

实验研究了15 Gy单次x射线局部照射大鼠实体可移植横纹肌肉瘤R1H后的减群和复群动力学。在照射后25天的时间间隔内依次测量几个参数:用流式细胞术测定肿瘤与宿主细胞的比例;通过组织切片的立体学分析得到肿瘤细胞的数值密度;取一定数量的肿瘤细胞,并对其菌落进行记分,检测肿瘤细胞的致克隆率;通过测量彼此成直角的两个肿瘤直径来评估肿瘤体积。除肿瘤体积外,所有被调查的参数在放疗后的前两周内都发生了剧烈的变化。从直接测量的参数可以得到下列值及其随时间的变化。在照射后的头10天内,每个肿瘤的宿主细胞数量增加了10倍,可能是由于血源性宿主细胞的浸润。在同一时间间隔内,肿瘤细胞的数量减少了5倍,而每个肿瘤的细胞总数增加了4倍。由于宿主细胞比肿瘤细胞小得多,细胞数量密度增加了3倍,但在照射后第18天接近对照水平。通过克隆性和非克隆性肿瘤细胞的数量,得到了肿瘤细胞再生和减少的动力学。在辐照后,存活的肿瘤细胞和灭活的肿瘤细胞立即开始增殖,并以指数动力学的方式进行。肿瘤细胞的再生时间为4.4±0.3天,而灭活的肿瘤细胞的降解时间为3.5±0.7天。没有迹象表明x射线照射后死亡细胞的增殖对肿瘤生长有显著的促进作用。
{"title":"Depopulation and repopulation of the R1H rhabdomyosarcoma of the rat after X-irradiation","authors":"H. Jung,&nbsp;H.-P. Beck,&nbsp;I. Brammer,&nbsp;F. Zywietz","doi":"10.1016/0014-2964(81)90245-0","DOIUrl":"10.1016/0014-2964(81)90245-0","url":null,"abstract":"<div><p>Experiments were carried out to study the kinetics of depopulation and repopulation of the solid transplantable rhabdomyosarcoma R<em>1</em>H of the rat following local irradiation with a single X-ray dose of <em>15 Gy</em>. Several parameters were sequentially measured over a time interval of <em>25 days</em> after irradiation: The ratio of tumour to host cells was determined by flow cytometry; the numerical density of tumour cells was obtained by stereological analysis of histological slides; the clonogenic fraction of tumour cells was assayed by plating an appropriate number of tumour cells and scoring the colonies; tumour volume was assessed by measuring two tumour diameters at right angles to each other. All parameters investigated, except tumour volume, undergo drastic changes during the first <em>2 weeks</em> after irradiation. From the directly measured parameters the following values and their variation with time could be derived. The number of host cells per tumour increased by a factor of <em>10</em> within the first <em>10 days</em> after irradiation, probably due to infiltration by blood-borne host cells. During the same time interval, the number of tumour cells decreased by a factor of <em>5</em>, whereas the total number of cells per tumour showed an increase by a factor of <em>4</em>. Since the host cells are considerably smaller than the tumour cells, the cellular numerical density increased by a factor of <em>3</em>, but approached the control level by <em>Day 18</em> after irradiation. From the number of clonogenic and non-clonogenic tumour cells the kinetics of repopulation and depopulation was obtained. Repopulation of irradiated tumours by surviving tumour cells as well as removal of inactivated tumour cells began immediately after irradiation and proceeded with exponential kinetics. Repopulation occurred with a doubling time of <em>4.4 ± 0.3 days</em> whereas inactivated tumour cells disintegrated with a halving time of <em>3.5 ± 0.7 days</em>. There were no indications that proliferation of doomed cells contributed significantly to tumour growth after X-irradiation.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 375-386"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90245-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18320786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 40
Partial purification and characterization of a cell specific G1-inhibitor (chalone) from JB-1 ascites tumors JB-1腹水肿瘤中细胞特异性g1抑制剂(chalone)的部分纯化和鉴定
Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90251-6
N.M. Barfod

Cell-specific G1-inhibitory (chalone) activity has been extracted from old JB-1 ascites tumors and purified by means of G-15 Sephadex chromatography. Four peaks of activity were obtained, the amount of activity in each peak varying from batch to batch. The first eluting activity peak probably represents chalone activity present in an aggregated form. The latest eluting activity peak was totally unspecific and could be attributed to the presence of high amounts of salts. The two intermediary peaks of activity were investigated in more detail. It is shown that the first eluting activity peak of these two is due to the polyamine spermine complexed to a carrier. Although the spermine complex exhibits a certain degree of cell-specific inhibitory activity in vitro, it is totally inactive in vivo. The second eluting activity peak containing the main part of cell-specific G-inhibitory activity has been characterized as a small molecular weight (Mr300–600), ampholytic, hydrophobic, slightly acidic, and thiol-containing peptide active both in vitro and in vivo.

从旧的JB-1腹水肿瘤中提取细胞特异性g1抑制(chalone)活性,并采用G-15 Sephadex层析纯化。得到了四个活性峰,每个峰的活性量随批次而变化。第一个洗脱活性峰可能代表以聚集形式存在的chalone活性。最新的洗脱活性峰是完全不特异的,可能是由于存在大量的盐。对两个中间活性峰进行了更详细的研究。结果表明,这两种方法的第一个洗脱活性峰是由多胺精胺与载体络合产生的。虽然精胺复合物在体外表现出一定程度的细胞特异性抑制活性,但在体内完全无活性。第二个洗脱活性峰含有细胞特异性g抑制活性的主要部分,其特征是分子量小(Mr300-600)、两性水解、疏水、微酸性、含硫醇肽,在体外和体内均具有活性。
{"title":"Partial purification and characterization of a cell specific G1-inhibitor (chalone) from JB-1 ascites tumors","authors":"N.M. Barfod","doi":"10.1016/0014-2964(81)90251-6","DOIUrl":"10.1016/0014-2964(81)90251-6","url":null,"abstract":"<div><p>Cell-specific G<sub><em>1</em></sub>-inhibitory (chalone) activity has been extracted from old JB-<em>1</em> ascites tumors and purified by means of G-<em>15</em> Sephadex chromatography. Four peaks of activity were obtained, the amount of activity in each peak varying from batch to batch. The first eluting activity peak probably represents chalone activity present in an aggregated form. The latest eluting activity peak was totally unspecific and could be attributed to the presence of high amounts of salts. The two intermediary peaks of activity were investigated in more detail. It is shown that the first eluting activity peak of these two is due to the polyamine spermine complexed to a carrier. Although the spermine complex exhibits a certain degree of cell-specific inhibitory activity <em>in vitro</em>, it is totally inactive <em>in vivo</em>. The second eluting activity peak containing the main part of cell-specific G-inhibitory activity has been characterized as a small molecular weight (<em>M</em><sub><em>r</em></sub><em>300–600</em>), ampholytic, hydrophobic, slightly acidic, and thiol-containing peptide active both <em>in vitro</em> and <em>in vivo</em>.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 421-431"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90251-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17517136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Expression of normal histocompatibility antigens in murine lymphomas treated with 5-(3,3′-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vivo 5-(3,3′-二甲基-1-三氮杂化)-咪唑-4-羧酰胺(DTIC)治疗小鼠淋巴瘤正常组织相容性抗原的体内表达
Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90250-4
D. Taramelli , L. Romani , A. Bonmassar , A. Goldin , M.C. Fioretti

Novel transplantation antigens have been detected in a Moloney virus-induced LSTRA lymphoma of BALB/c origin (H-2d), or in a chemically-induced L5178Y lymphoma of DBA/2 origin, following treatment of tumor-bearing hosts with 5-(3,3′-dimethyl-1-triazeno-)-imidazole-4-carboxamide (DTIC), for 4–8 transplant generations. Marked cell-mediated cytotoxic responses against DTIC-treated LSTRA or L5178Y lines were found by primary in vivo and secondary in vitro sensitization of histocompatible mice. Moreover, preliminary data show that no obvious antigenic cross-reactivity can be found among DTIC-treated sublines derived from distinct parental lymphomas. To test whether DTIC lines would express variable levels of normal histocompatibility antigens, cytotoxic lymphocytes were generated in vitro against alloantigens of H-2 complex or sub-regions of it and tested against parental or DTIC-treated lymphomas in a short-term 51Cr-release assay. A cold-inhibition test was performed with LSTRA or 4 LSTRA/DTIC sublines. The results showed that little or no difference in the expression of H-2 antigens recognized by cytotoxic lymphocytes could be detected between parental and DTIC-treated sublines. Moreover, no foreign H-2 specificities of H-2b or H-2k haplotypes detectable by cytotoxic lymphocytes could have been found in L5178Y or L5178Y/DTIC lymphomas.

在5-(3,3 ' -二甲基-1-三氮杂-)-咪唑-4-carboxamide (DTIC)治疗肿瘤宿主4-8代移植后,在Moloney病毒诱导的BALB/c来源的LSTRA淋巴瘤(H-2d)或化学诱导的DBA/2来源的L5178Y淋巴瘤中发现了新的移植抗原。通过对组织相容性小鼠的一次体内和二次体外致敏,发现dtic处理的LSTRA或L5178Y细胞系有明显的细胞介导的细胞毒性反应。此外,初步数据显示,在来自不同亲代淋巴瘤的dtic治疗亚群中,没有发现明显的抗原交叉反应性。为了测试DTIC细胞系是否能表达不同水平的正常组织相容性抗原,我们在体外生成针对H-2复合物或其亚区同种抗原的细胞毒淋巴细胞,并在短期51cr释放试验中检测对亲本或DTIC治疗的淋巴瘤的杀伤作用。用LSTRA或4个LSTRA/DTIC亚系进行冷抑制试验。结果显示,亲本和dtic处理的亚群在细胞毒性淋巴细胞识别的H-2抗原表达上几乎没有差异。此外,在L5178Y或L5178Y/DTIC淋巴瘤中未发现细胞毒性淋巴细胞检测到的H-2b或H-2k单倍型的外来H-2特异性。
{"title":"Expression of normal histocompatibility antigens in murine lymphomas treated with 5-(3,3′-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vivo","authors":"D. Taramelli ,&nbsp;L. Romani ,&nbsp;A. Bonmassar ,&nbsp;A. Goldin ,&nbsp;M.C. Fioretti","doi":"10.1016/0014-2964(81)90250-4","DOIUrl":"10.1016/0014-2964(81)90250-4","url":null,"abstract":"<div><p>Novel transplantation antigens have been detected in a Moloney virus-induced LSTRA lymphoma of BALB/c origin (<em>H-2<sup>d</sup></em>), or in a chemically-induced <em>L5178Y</em> lymphoma of <em>DBA/2</em> origin, following treatment of tumor-bearing hosts with <em>5-(3,3</em>′-dimethyl-<em>1</em>-triazeno-)-imidazole-<em>4</em>-carboxamide (DTIC), for <em>4–8</em> transplant generations. Marked cell-mediated cytotoxic responses against DTIC-treated LSTRA or <em>L5178Y</em> lines were found by primary <em>in vivo</em> and secondary <em>in vitro</em> sensitization of histocompatible mice. Moreover, preliminary data show that no obvious antigenic cross-reactivity can be found among DTIC-treated sublines derived from distinct parental lymphomas. To test whether DTIC lines would express variable levels of normal histocompatibility antigens, cytotoxic lymphocytes were generated <em>in vitro</em> against alloantigens of <em>H-2</em> complex or sub-regions of it and tested against parental or DTIC-treated lymphomas in a short-term <em><sup>51</sup>Cr</em>-release assay. A cold-inhibition test was performed with LSTRA or <em>4</em> LSTRA/DTIC sublines. The results showed that little or no difference in the expression of <em>H-2</em> antigens recognized by cytotoxic lymphocytes could be detected between parental and DTIC-treated sublines. Moreover, no foreign <em>H-2</em> specificities of <em>H-2<sup>b</sup></em> or H-<em>2<sup>k</sup></em> haplotypes detectable by cytotoxic lymphocytes could have been found in <em>L5178Y</em> or <em>L5178Y</em>/DTIC lymphomas.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 411-420"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90250-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17236852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Absence of antigens related to murine mammary tumour virus polypeptides in rat mammary tumours 大鼠乳腺肿瘤中缺乏与鼠乳腺肿瘤病毒多肽相关的抗原
Pub Date : 1981-04-01 DOI: 10.1016/0014-2964(81)90249-8
P. Bentvelzen , F. Westenbrink , J.J. Broerse , M.J. Van Zwieten

Fifty-two rat mammary tumours were tested by radioimmunoassay for the presence of antigens related to the envelope glycoprotein gp52 and core protein p28 of the murine mammary tumour virus and found to be negative. The tumours assayed were from WAG/Rij (16 cases), BN/BiRij (16 cases) and Sprague—Dawley (20 cases) rats. Thirty of the rats had been irradiated with fast neutrons, 16 with X-rays, one had been implanted with a 17-β-oestradiol pellet and 5 were untreated. The tumours studied included 22 fibroadenomas, 2 adenomas, 19 adenocarcinomas, 4 sarcomas, 1 carcinosarcoma, and 4 of undetermined type.

用放射免疫法对52例大鼠乳腺肿瘤进行了小鼠乳腺肿瘤病毒包膜糖蛋白gp52和核心蛋白p28相关抗原的检测,结果均为阴性。WAG/Rij大鼠16例,BN/BiRij大鼠16例,Sprague-Dawley大鼠20例。其中30只大鼠接受了快中子照射,16只接受了x射线照射,1只被植入了17-β-雌二醇颗粒,5只未接受治疗。研究的肿瘤包括22例纤维腺瘤、2例腺瘤、19例腺癌、4例肉瘤、1例癌肉瘤和4例类型未确定的肿瘤。
{"title":"Absence of antigens related to murine mammary tumour virus polypeptides in rat mammary tumours","authors":"P. Bentvelzen ,&nbsp;F. Westenbrink ,&nbsp;J.J. Broerse ,&nbsp;M.J. Van Zwieten","doi":"10.1016/0014-2964(81)90249-8","DOIUrl":"10.1016/0014-2964(81)90249-8","url":null,"abstract":"<div><p>Fifty-two rat mammary tumours were tested by radioimmunoassay for the presence of antigens related to the envelope glycoprotein gp<em>52</em> and core protein p<em>28</em> of the murine mammary tumour virus and found to be negative. The tumours assayed were from WAG/Rij (<em>16</em> cases), BN/BiRij (<em>16</em> cases) and Sprague—Dawley (<em>20</em> cases) rats. Thirty of the rats had been irradiated with fast neutrons, <em>16</em> with X-rays, one had been implanted with a <em>17</em>-β-oestradiol pellet and <em>5</em> were untreated. The tumours studied included <em>22</em> fibroadenomas, <em>2</em> adenomas, <em>19</em> adenocarcinomas, <em>4</em> sarcomas, <em>1</em> carcinosarcoma, and <em>4</em> of undetermined type.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 4","pages":"Pages 407-410"},"PeriodicalIF":0.0,"publicationDate":"1981-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90249-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17335928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
European Journal of Cancer (1965)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1